
The study aimed to determine the optimal duration of bedaquiline (BDQ) treatment for patients with rifampicin- and multidrug-resistant tuberculosis. The researchers conducted a simulated trial using a three-step approach to estimate the effect of three BDQ treatment strategies (6, 7-11, and ≥12 months) on the probability of successful treatment. The analysis included 1,468 participants who received a median of 4 effective drugs, including linezolid and clofazimine. The adjusted probability of successful treatment was 0.85 for 6 months of BDQ, 0.77 for 7-11 months, and 0.86 for ≥12 months. However, when accounting for bias, the difference between the treatment durations was not significant, suggesting that BDQ use beyond 6 months may not increase treatment success.
Like
Save
Share